Frankfurt - Delayed Quote EUR

Astellas Pharma Inc. (YPHA.F)

8.20

+0.05

+(0.61%)

As of 8:02:10 AM GMT+2. Market Open.

Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio

Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced DeepSeq.AI, Inc. & Serna Bio as the winners of the Astellas sponsored Future Innovator Prize at MBC BioLabs. The award, now in its sixth year, offers entrepreneurial scientists, emerging startups and small biotechs one-year priority usage of MBC BioLabs' state-of-the-art lab facility in the San Francisco Bay Area, as well as acc

PR Newswire 19 hours ago

ALPMF

ALPMY
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3). The research underscores Astellas' dedication as a pioneer in oncology and focus on clinical outcomes that matter to patients.

PR Newswire 2 days ago

ALPMF

ALPMY
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now

Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 8 days ago

ALPMY
Astellas CEO on Outlook Ahead of Trump's Pharma Tariffs

The global pharmaceutical industry is grappling with an uncertain outlook, amid President Donald Trump's plans to cut US prescription drug prices and impose tariffs on pharma imports. Astellas Pharma is among the Japanese drug makers that depends on the US for a large chunk of sales. CEO Naoki Okamura spoke to Bloomberg TV in Tokyo on May 7th about the impact of Trump's tariffs, and the firm's engagement with activist investor Farallon Capital Management.

Bloomberg 9 days ago

ALPMY
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

(Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R

Bloomberg 10 days ago

C

TAK

TKPHF
Notice of Nominees for Directors

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that during a meeting of its Board of Directors held today, it decided a change in Directors as outlined below. The appointment of Andreas Busch and Mark Enyedy as new candidates to be proposed at the 20th Term Annual Shareholders Meeting scheduled for June 19, 2025, represents a significant move in the company's continuous evolution, aimed at enhancing the diverse composition of our Board of Directors

PR Newswire 15 days ago

ALPMF

ALPMY
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), maker of IZERVAY™ (avacincaptad pegol intravitreal solution), a C5 inhibitor for the treatment of geographic atrophy (GA)*, will highlight new data that enhances continued understanding of the science of GA, and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 4-8, Salt Lake City, Utah, and Retina World Congress (RWC)

PR Newswire 20 days ago

ALPMF

ALPMY
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?

Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 22 days ago

ALPMY
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

Zacks 23 days ago

ALPMY

ANGO
Astellas Pharma and JFCR partner for oncology research

The agreement stipulates that projects will be co-selected, drawing on shared interests and areas of expertise.

Pharmaceutical Technology last month

ALPMY
Astellas and Yaskawa form JV for cell therapy product manufacture

The JV will leverage the dual-arm robot Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.

Pharmaceutical Technology 2 months ago

ALPMY
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa, "YASKAWA") signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot "Maholo." In addition, the joint venture will offer platform access to startups and academic institutions, fostering collaboration and innovation in the field of cell therap

PR Newswire 2 months ago

YASKF

YASKY

ALPMF
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the Astellas Future Innovator Prize. The competition offers entrepreneurial scientists and emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art Bay Area facilities and access to Astellas' research and development capabilities and business leaders.

PR Newswire 2 months ago

ALPMF

ALPMY
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing GA.

PR Newswire 3 months ago

ALPMF

ALPMY
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

On Monday, Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook The results showed a sustained overall

Benzinga 3 months ago

PFE

ALPMY
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

Pfizer (PFE) and Astellas Pharma said additional follow-up results from a phase 3 clinical trial of

PREMIUM
MT Newswires 3 months ago

PFE

ALPMY
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

NEW YORK & TOKYO, February 10, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothe

Business Wire 3 months ago

PFE

ALPMF

ALPMY
Astellas seeks conditional approval for GA treatment in Japan

The application is supported by outcomes from the GATHER1 and GATHER2 studies.

Pharmaceutical Technology 3 months ago

ALPMY
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for Conditional Approval of avacincaptad pegol intravitreal solution (ACP), a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD. If approved, ACP has the potential to become the first and only GA treatment available in Japan.

PR Newswire 3 months ago

ALPMF

ALPMY
Astellas Makes Announcement about Management Structure

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.

PR Newswire 3 months ago

ALPMF

ALPMY

Performance Overview

Return	YPHA.F	Nikkei 225 (^N225)
YTD	-8.89%	-7.29%
1-Year	-1.72%	-4.22%
3-Year	-34.69%	+38.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Astellas Pharma Inc. (YPHA.F)

Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio

Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting

Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now

Astellas CEO on Outlook Ahead of Trump's Pharma Tariffs

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Notice of Nominees for Directors

Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses

Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?

Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Astellas Pharma and JFCR partner for oncology research

Astellas and Yaskawa form JV for cell therapy product manufacture

Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing

Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Astellas seeks conditional approval for GA treatment in Japan

Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Makes Announcement about Management Structure

Performance Overview